AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30122926
Drug: Asenapine 2.5
RxNorm normalized name: asenapine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 2.5 mg BID
Trial: 30122926
Drug: Asenapine 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 5.0 mg BID
Trial: 30122926
Drug: Asenapine 10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 10.0 mg BID
Trial: 30123524
Drug: Positive Mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Mental Imagery Training (PMIT) + Treatment as Usual (TAU)
Trial: 30123524
Drug: Cognitive Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Control Training (CCT) + Treatment as Usual (TAU)
Trial: 30123523
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion (targeted to heart rate 80-90/min)
Trial: 30123673
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice daily during the first 3 cycles of VCD induction therapy
Trial: 30123673
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice daily during the first 3 cycles of VCD induction therapy
Trial: 30123846
Drug: Herbal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal formulation (HB)
Trial: 30126674
Drug: Pfs25 VLP-FhCMB
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfs25 VLP-FhCMB vaccine combined with Alhydrogel® adjuvant
Trial: 30126674
Drug: Pfs25 VLP-FhCMB
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfs25 VLP-FhCMB vaccine
Trial: 30126765
Drug: Enzalutamide 1L
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 1L treatment (chemo-naive)
Trial: 30126765
Drug: Enzalutamide 2L
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 2L treatment (post-docetaxel or -abiraterone)
Trial: 30126765
Drug: Enzalutamide 3L
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 3L or 4L treatment
Trial: 30126765
Drug: Enzalutamide 3L
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 3L or 4L treatment (fatigue)
Trial: 30126861
Drug: Paclitaxel (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (70 mg/m2)
Trial: 30126891
Drug: Multifaceted medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted medication reconciliation quality improvement intervention
Trial: 30126953
Drug: ETX2514SUL (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETX2514SUL (combination of ETX2514 and sulbactam)
Trial: 30127621
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of oral osimertinib, oral temozolomide, intrathecal cytarabine, and whole-brain radiation therapy
Trial: 30128164
Drug: Individualised telemedicine
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualised telemedicine cognitive behavioural therapy (CBT)-based intervention
Trial: 30128316
Drug: Drisapersen 6
RxNorm normalized name: drisapersen
DrugBank: Drisapersen (DB13688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drisapersen 6 mg/kg/week for 24 weeks
Trial: 30128316
Drug: Drisapersen 3
RxNorm normalized name: drisapersen
DrugBank: Drisapersen (DB13688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drisapersen 3 mg/kg/week for 24 weeks
Trial: 30128502
Drug: PVX-410 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVX-410 vaccine (0.4 mg total, 0.1 mg/peptide, n=3) or (0.8 mg total, 0.2 mg/peptide, n=9) biweekly via subcutaneous injection, plus 0.5 mL (1 mg) poly-ICLC (2 mg/mL) via intramuscular injection with each dose.
Trial: 30128502
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PVX-410 vaccine with lenalidomide (25 mg orally daily for three 21-day cycles, n=10).
Trial: 30128502
Drug: PVX-410 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVX-410 vaccine alone (monotherapy).
Trial: 30128605
Drug: Intravitreal decorin
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal decorin 200 μg
Trial: 30128605
Drug: Intravitreal decorin
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal decorin 400 μg
Trial: 30129045
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance (RM) after R-CHOP-based induction therapy
Trial: 30129045
Drug: R-CHOP-based induction
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP-based induction therapy
Trial: 30131059
Drug: Inconsistently moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inconsistently moderate drinkers (males: 1-168 g ethanol/week; females: 1-112 g ethanol/week)
Trial: 30131748
Drug: Occupational Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational Therapy
Trial: 30134131
Drug: Nivolumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (1 mg/kg) plus Ipilimumab (3 mg/kg) every 3 weeks for up to four doses, followed by Nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects
Trial: 30134131
Drug: Nivolumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (1 mg/kg) plus Ipilimumab (3 mg/kg)
Trial: 30135755
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive behavioural therapy (CCBT) with Internet Support Group (ISG)
Trial: 30135755
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive behavioural therapy (CCBT) without Internet Support Group (ISG)
Trial: 30135764
Drug: Unguided internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided internet-delivered cognitive-behavioral therapy for insomnia (ICBTi)
Trial: 30135764
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Cognitive-behavioral therapy for insomnia)
Trial: 30137238
Drug: TFV disoproxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFV disoproxil fumarate (TDF)-based therapy
Trial: 30137396
Drug: Homeostasis model
RxNorm normalized name: CALCIUM HOMEOSTASIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeostasis model assessment for insulin resistance
Trial: 30137406
Drug: Higher bioavailable
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher bioavailable testosterone, free testosterone, dehydroepiandrosterone (DHEA), and lower sex hormone-binding globulin (SHBG) levels
Trial: 30137598
Drug: Daily sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sleep duration and variability measured by wrist actigraphy
Trial: 30138022
Drug: brief cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brief cognitive-behavioral therapy (bCBT)
Trial: 30139372
Drug: Clofazimine (CFZ)
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine (CFZ) administered orally for 5 days
Trial: 30139372
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally for 5 days
Trial: 30139779
Drug: CXCR2 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CXCR2 antagonist danirixin
Trial: 30139840
Drug: Linsitinib 450
RxNorm normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linsitinib 450 mg daily on days 1-3 every 7 days and irinotecan 125 mg/m²
Trial: 30139840
Drug: Linsitinib 400
RxNorm normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linsitinib 400 mg and irinotecan 100 mg/m²
Trial: 30139897
Drug: Medication intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication intake
Trial: 30139903
Drug: MK-7 (720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7 (720 µg/day) supplemented by vitamin D (25 µg/day)
Trial: 30139903
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (no active treatment)
Trial: 30142084
Drug: 12 week
RxNorm normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 week supervised exercise therapy alone
Trial: 30142422
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fish oil (FO) and cytarabine (AraC)
Trial: 30143455
Drug: Loss to
RxNorm normalized name: SALICYLIC ACID 0.3 in 100 mL / NIACINAMIDE 0.3 in 100 mL / MENTHOL 0.3 in 100 mL TOPICAL LIQUID [PHS Hair Science Fem Hair Loss Tonic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loss to follow-up after starting treatment
Trial: 30143455
Drug: Treatment initiation
RxNorm normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment initiation likelihood based on site type
Trial: 30146701
Drug: ZX008 (fenfluramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZX008 (fenfluramine HCl) at an initial dose of 0.2 mg/kg/d, with escalations up to 0.8 mg/kg/d or 30 mg/d every 4 weeks in nonresponders.
Trial: 30146701
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events related to ZX008 treatment.
Trial: 30149145
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (canagliflozin)
Trial: 30149145
Drug: Incretin agents
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incretin agents (liraglutide)
Trial: 30149145
Drug: Incretin agents
RxNorm normalized name: Secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incretin agents (sitagliptin)
Trial: 30151972
Drug: Marzeptacog alfa
RxNorm normalized name: Marzeptacog alfa (activated)
DrugBank: Marzeptacog alfa (activated) (DB15278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marzeptacog alfa (activated) at intravenous doses up to 30 μg kg
Trial: 30152164
Drug: Hybrid cognitive-behavioral
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid cognitive-behavioral therapy intervention
Trial: 30153232
Drug: Ceftolozane/tazobactam (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/tazobactam (single intravenous dose, age-based)
Trial: 30153232
Drug: Ceftolozane/tazobactam (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/tazobactam (single intravenous dose)
Trial: 30153529
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone deficiency (GHD) patients after aerobic exercise
Trial: 30153790
Drug: High-dose behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose behavioral treatment (DTI plus relaxation training)
Trial: 30153790
Drug: Low-dose behavioral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose behavioral treatment (DTI plus relaxation training)
Trial: 30154193
Drug: Intratumoral SD-101
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral SD-101 in combination with pembrolizumab
Trial: 30154228
Drug: Hsp90 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hsp90 inhibitor luminespib (formerly AUY922)
Trial: 30154228
Drug: EGFR inhibitors
RxNorm normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR inhibitors (first-, second-, and third-generation)
Trial: 30154229
Drug: Annual MG
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual MG screening plus biannual MRI screening
Trial: 30155282
Drug: HTC-gel (Thealoz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTC-gel (Thealoz Duo Gel) - hyaluronic acid, trehalose, and carbomer
Trial: 30156984
Drug: Capmatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capmatinib (400 mg twice per day) plus Gefitinib (250 mg once per day)
Trial: 30156984
Drug: Capmatinib (100-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capmatinib (100-800 mg once per day or 200-600 mg twice per day) plus Gefitinib (250 mg once per day)
Trial: 30157702
Drug: HPTN 052
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPTN 052 clinical trial care and treatment
Trial: 30157803
Drug: Accelerated BEP
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated BEP chemotherapy
Trial: 30157803
Drug: Standard BEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard BEP chemotherapy
Trial: 30158288
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg per day for 56 days
Trial: 30158840
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with HBOT for 10 sessions (combination therapy)
Trial: 30161147
Drug: Option B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Option B PMTCT regimen (three-drug ART throughout pregnancy and breastfeeding, regardless of maternal CD4 count)
Trial: 30165500
Drug: Fruit consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruit consumption in RTRs with eGFR > 45 mL/min/1.73 m2
Trial: 30165651
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of live herpes zoster vaccine (ZVL)
Trial: 30166073
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg twice daily) plus aspirin (75-100 mg daily) for 1 month, followed by ticagrelor monotherapy for 23 months
Trial: 30166073
Drug: Standard dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dual antiplatelet therapy (75-100 mg aspirin daily plus either 75 mg clopidogrel daily or 90 mg ticagrelor twice daily for 12 months), followed by aspirin monotherapy for 12 months
Trial: 30166291
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) syndrome-targeted therapies
Trial: 30166291
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) four diagnostic methods
Trial: 30167089
Drug: Alpelisib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib (300 mg, n=6) plus paclitaxel (80 mg/m2)
Trial: 30167089
Drug: Alpelisib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib (250 mg, n=4) plus paclitaxel (80 mg/m2)
Trial: 30167089
Drug: Alpelisib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib (150 mg, n=9) plus paclitaxel (80 mg/m2)
Trial: 30167310
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg two times a day
Trial: 30168134
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1·8 mg/kg intravenously once every 3 weeks)
Trial: 30168356
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) in addition to physiotherapy
Trial: 30169182
Drug: AAV2-hAADC gene
RxNorm normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV2-hAADC gene therapy (bilateral intraputaminal injections, dosage not specified)
Trial: 30169223
Drug: Elvitegravir 150
RxNorm normalized name: elvitegravir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once daily
Trial: 30169669
Drug: Low antenatal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low antenatal vitamin D status (<30 nmol/L and <50 nmol/L)
Trial: 30169669
Drug: Maternal 25(OH)D
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal 25(OH)D (per 10 nmol/L)
Trial: 30169669
Drug: Cord 25(OH)D
RxNorm normalized name: cow umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord 25(OH)D (per 10 nmol/L)
Trial: 30170630
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg) and low-dose ipilimumab (1 mg/kg)
Trial: 30170630
Drug: Empiric immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric immune suppressive therapy (high dose steroids, tacrolimus, therapeutic plasma exchange)
Trial: 30171797
Drug: Measles-mumps-rubella vaccine
RxNorm normalized name: MEASLES/MUMPS/RUBELLA VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measles-mumps-rubella vaccine (MMR)
Trial: 30172345
Drug: R2-CHOP (Rituximab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R2-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone + 25 mg oral Lenalidomide per day on days 1-14 for 6 cycles every 3 weeks)
Trial: 30172739
Drug: Estimated antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimated antipsychotic dopamine receptor occupancy
Trial: 30173210
Drug: Intracavernous autologous
RxNorm normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracavernous autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) injections
Trial: 30174951
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg and pregabalin 75mg twice daily starting from 3 days before the operation
Trial: 30175123
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone implant (Ozurdex, Allergan)
Trial: 30176833
Drug: Radiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy and hormonal therapy
Trial: 30176875
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow concentrate (BMC) and platelet products injection
Trial: 30176878
Drug: Iconic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iconic Therapy
Trial: 30176878
Drug: Structured Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Support Therapy
Trial: 30176976
Drug: Positive Airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Airway Pressure (PAP) therapy adherence (h/night)
Trial: 30177021
Drug: Fostamatinib (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib (an oral prodrug SYK inhibitor)
Trial: 30178032
Drug: Nab-paclitaxel (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (125 mg/m2) plus gemcitabine (1000 mg/m2) administered on days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxic effects.
Trial: 30178312
Drug: Homozygous G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homozygous G mutant
Trial: 30178312
Drug: Gln27Glu G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gln27Glu G mutant group
Trial: 30178481
Drug: CTL019 infusion
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTL019 infusion
Trial: 30179569
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (Bv) 1.8 mg/kg once every 3 weeks followed by six cycles of AVD chemotherapy and four consolidative doses of Bv